British cannabis-derived medicines company GW Pharma is planning to gear up its plant growing and processing operations in the UK over the next year.
The firm, which switched a listing on London’s junior market Aim for New York’s Nasdaq last year, where it has a market value of $2.6bn (£2bn), is committing to expanding in the UK.
It grows several tons of specially-modified cannabis plants a year – which have had the chemicals that result in a high genetically edited out – in British Sugar’s 44-acre greenhouse in Norfolk. It then processes and purifies the plant material in the UK to make medicines, mostly for export to the massive US market.
GW has one approved medicine, an oral spray called Sativex for treating the muscle spasticity associated with the condition multiple sclerosis.
Read the Full Story at the Telegraph
Read More